Tag: Calprotectin Assays

Clinical Utility of Fecal Calprotectin Monitoring in Asymptomatic Patients with Inflammatory Bowel Disease: A Systematic Review and Practical Guide

BÜHLMANN fCAL® ELISA: Heidi A, Park KT, Rheenen PF. Clinical Utility of Fecal Calprotectin Monitoring in Asymptomatic Patients with Inflammatory Bowel Disease: A Systematic Review and Practical Guide. Inflamm Bowel Dis. 2017 Jun;23(6):894-902. doi: 10.1097/MIB.0000000000001082. PMID: 28511198 Highlights from this Publication “This systematic review shows that the relapsing remitting nature of IBD becomes less unpredictable

Visit BUHLMANN at DDW 2017- Booth 1925

Digestive Diseases Week (DDW) 2017 BUHLMANN Diagnostics Corp Booth: #1925 May 06 - 09, 2017 | McCormick Place | Chicago, IL Learn More Click & Contact DDW 2017 BUHLMANN Team Connect with our team ahead of time, learn more about our Calprotectin Assays or schedule a meeting! Collin Shaw, VP of Business Development Jennifer Stuart, Technical

BÜHLMANN Laboratories AG (BL), based in Basel Switzerland, has been discovering, developing & manufacturing innovative chemistry and immunological in-vitro diagnostic (IVD) and research use only (RUO) assays for almost 50 years (circa 1976). As the United States commercial affiliate of BL, BUHLMANN Diagnostics Corp (BDC), based in Amherst, NH is committed to providing exceptional sales, support, and technical services to our clinical, discovery and basic science research laboratory customers.

Tag: Calprotectin Assays

Clinical Utility of Fecal Calprotectin Monitoring in Asymptomatic Patients with Inflammatory Bowel Disease: A Systematic Review and Practical Guide

Visit BUHLMANN at DDW 2017- Booth 1925

ABOUT US

SOCIAL MEDIA

QUICK LINKS

CONTACT US